<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005980</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-10993-16998</org_study_id>
    <secondary_id>EORTC-IDBBC-10993</secondary_id>
    <secondary_id>ECSG-10993</secondary_id>
    <secondary_id>PAMM-10993</secondary_id>
    <nct_id>NCT00005980</nct_id>
  </id_info>
  <brief_title>Comparison of Two Regimens of Liposomal Doxorubicin in Treating Women With Metastatic Breast Cancer</brief_title>
  <official_title>A Randomized Phase II Study of Two Different Schedules of Caelyx in Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. It is not yet known which regimen of liposomal doxorubicin is more
      effective for metastatic breast cancer.

      PURPOSE: Randomized phase II trial to compare the effectiveness of two regimens of liposomal
      doxorubicin in treating women who have metastatic breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the response rate in women with metastatic breast cancer treated with two
           different dose schedules of doxorubicin HCL liposome.

        -  Assess the side effects of these treatment regimens in this patient population.

        -  Determine the duration of response in these patients treated with these regimens.

        -  Assess the concentration of doxorubicin in tumor tissue in patients with easily
           accessible metastases.

      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to
      participating center, performance status (0-1 vs 2), visceral disease (yes vs no), available
      lesions for biopsy (yes vs no), prior adjuvant anthracyclines (yes vs no), and prior
      chemotherapy for advanced disease (yes vs no). Patients are randomized to one of two
      treatment arms.

        -  Arm I: Patients receive doxorubicin HCL liposome IV over 1 hour every 6 weeks.

        -  Arm II: Patients receive doxorubicin HCL liposome IV over 1 hour every 4 weeks.
           Treatment continues for at least 36 weeks in the absence of disease progression or
           unacceptable toxicity.

      Patients are followed every 3 months.

      PROJECTED ACCRUAL: A total of 64-100 patients (32-50 per treatment arm) will be accrued for
      this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2000</start_date>
  <primary_completion_date type="Actual">July 2002</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">116</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegylated liposomal doxorubicin hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically proven progressive or recurrent metastatic breast cancer

          -  Bidimensionally measurable disease with at least one target lesion

               -  If previously irradiated lesions:

                    -  No preirradiated only lesions

                    -  Clear progression prior to study

                    -  New lesions in a previously irradiated region allowed

          -  Refusal of or medical contraindication to standard anthracycline containing regimen

          -  Hormone receptor status:

               -  Not specified

        PATIENT CHARACTERISTICS:

        Age:

          -  Any age

        Sex:

          -  Female

        Menopausal status:

          -  Not specified

        Performance status:

          -  ECOG 0-2

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Neutrophil count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

        Hepatic:

          -  Bilirubin normal

          -  Transaminases less than 2 times upper limit of normal

        Renal:

          -  Creatinine normal

        Cardiovascular:

          -  Left ventricular ejection fraction normal by echocardiography or MUGA scan

          -  No significant cardiac history including:

               -  Clinically significant atrial or ventricular arrhythmias requiring treatment

               -  Medically controlled congestive heart failure

               -  Significant angina or clinically and/or electrocardiographically documented
                  myocardial infarction within the past year

               -  Clinically significant valvular disease

        Other:

          -  No other prior or concurrent malignancy within the past 5 years except contralateral
             breast cancer, or adequately treated basal cell skin cancer or carcinoma in situ of
             the cervix

          -  No psychological, familial, sociological, or geographical condition that would
             preclude study

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  See Disease Characteristics

          -  Prior adjuvant chemotherapy allowed if total doxorubicin dose is no greater than 300
             mg/m2, total epirubicin dose is no greater than 450 mg/m^2, and total mitoxantrone
             dose is no greater than 75 mg/m^2

          -  No greater than one regimen of prior chemotherapy for metastatic disease

          -  No prior anthracyclines for metastatic disease

          -  No other concurrent cytotoxic therapy

        Endocrine therapy:

          -  No concurrent hormonal therapy

          -  At least 4 weeks since prior progestins, estrogens, or androgens

        Radiotherapy:

          -  See Disease Characteristics

          -  Concurrent palliative radiotherapy allowed if sole target lesion is outside irradiated
             field

        Surgery:

          -  Not specified

        Other:

          -  Concurrent bisphosphonates for metastatic bone disease and hypercalcemia secondary to
             malignancy allowed if bony lesions not only target lesion

          -  No other concurrent investigational therapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert E. Coleman, MD, FRCP</last_name>
    <role>Study Chair</role>
    <affiliation>Cancer Research Centre at Weston Park Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maurizio D'Incalci, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mario Negri Institute for Pharmacological Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christian Dittrich, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ludwig Boltzmann Institute for Applied Cancer Research at Kaiser Franz Josef Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ludwig Boltzmann - Institute for Applied Cancer Research</name>
      <address>
        <city>Vienna</city>
        <zip>A-1100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie - Section Medicale</name>
      <address>
        <city>Paris</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ioannina</name>
      <address>
        <city>Ioannina</city>
        <zip>GR-45110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center - Beilinson Campus</name>
      <address>
        <city>Petah-Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mario Negri Institute for Pharmacological Research</name>
      <address>
        <city>Milano (Milan)</city>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituti Fisioterapici Ospitalieri - Roma</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 EZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <zip>NL-6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique De Genolier</name>
      <address>
        <city>Genolier</city>
        <zip>Ch-1272</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden NHS Trust</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>Greece</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Biganzoli L, Coleman R, Minisini A, Hamilton A, Aapro M, Therasse P, Mottino G, Bogaerts J, Piccart M. A joined analysis of two European Organization for the Research and Treatment of Cancer (EORTC) studies to evaluate the role of pegylated liposomal doxorubicin (Caelyx) in the treatment of elderly patients with metastatic breast cancer. Crit Rev Oncol Hematol. 2007 Jan;61(1):84-9. Epub 2006 Nov 20.</citation>
    <PMID>17116400</PMID>
  </reference>
  <results_reference>
    <citation>Coleman RE, Biganzoli L, Canney P, Dirix L, Mauriac L, Chollet P, Batter V, Ngalula-Kabanga E, Dittrich C, Piccart M. A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993). Eur J Cancer. 2006 May;42(7):882-7. Epub 2006 Mar 7.</citation>
    <PMID>16520033</PMID>
  </results_reference>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 17, 2012</last_update_submitted>
  <last_update_submitted_qc>July 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

